BCL2 and neoplasm: Furthermore, inhibition of the NMT1/VILIP3/NFκB/Bcl-2 regulatory axis was observed in the desloratadine-treated PDX#1 and PDX#2 tumor xenografts, as indicated by Western blot (Fig. 6g).